dc.contributor.author | SESTAK, IVANA | |
dc.contributor.author | CUZICK, J | |
dc.contributor.author | Martín, M | |
dc.contributor.author | Dubsky, P | |
dc.contributor.author | Kronenwett, R | |
dc.contributor.author | Rojo, F | |
dc.contributor.author | Filipits, M | |
dc.contributor.author | Ruiz, A | |
dc.contributor.author | Gradishar, W | |
dc.contributor.author | Soliman, H | |
dc.contributor.author | Schwartzberg, L | |
dc.contributor.author | Buus, R | |
dc.contributor.author | Hlauschek, D | |
dc.contributor.author | Rodríguez-Lescure, A | |
dc.contributor.author | Gnant, M | |
dc.date.accessioned | 2019-05-20T12:53:48Z | |
dc.date.available | 2019-04-06 | |
dc.date.available | 2019-05-20T12:53:48Z | |
dc.date.issued | 2019-04-30 | |
dc.identifier.citation | Sestak, I., Martín, M., Dubsky, P. et al. Breast Cancer Res Treat (2019). https://doi.org/10.1007/s10549-019-05226-8 | en_US |
dc.identifier.issn | 0167-6806 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/57640 | |
dc.description.abstract | PURPOSE:
EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET + C).
METHODS:
A total of 3746 women were included in this joint analysis. 2630 patients received 5 years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET + C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET + C. Cox proportional hazard models were used for these analyses.
RESULTS:
EPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P < 0.0001) as well as in those who received ET + C (HR 2.27 (1.99-2.59), P < 0.0001). Women who received ET + C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin = 5; 12% ET + C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-interaction = 0.022).
CONCLUSIONS:
In this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET + C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease. | en_US |
dc.description.sponsorship | Cancer Research UK (C569/A16891) | en_US |
dc.description.sponsorship | Myriad Genetics | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer US | en_US |
dc.relation.ispartof | Breast Cancer Research and Treatment | |
dc.rights | “This is a post-peer-review, pre-copyedit version of a protocol published in Breast Cancer Research and Treatment. The final publication is available at link.springer.com: https://doi.org/10.1007/s10549-019-05226-8" | |
dc.subject | Breast cancer | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | EndoPredict | en_US |
dc.subject | Prediction | en_US |
dc.title | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone | en_US |
dc.type | Article | en_US |
dc.rights.holder | © The Author(s) 2019 | |
dc.identifier.doi | https://doi.org/10.1007/s10549-019-05226-8 | |
pubs.notes | Not known | en_US |
pubs.publication-status | Accepted | en_US |
dcterms.dateAccepted | 2019-04-06 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |